. 2007 Jun 20;18(4):326–334. doi: 10.1111/j.1399-3038.2007.00512.x

Table 4.

Multivariate analysis of effects of prednisolone for primary and secondary outcomes

Outcome	n	Int.	All patients	p‐value	Interactions between study drug and viral groups
					Rhinovirus		p‐value	Enterovirus		p‐value
					Yes	No.	p‐value	Yes	No	p‐value
Time until ready for discharge, h	58	Pred.	18 (6–34)	0.11	6 (6–30)	21 (6–42)	0.37	6 (6–18)	30 (6–42)	0.0007*
Time until ready for discharge, h	58	Pl.	24 (6–42)	0.11	28 (18–54)	21 (6–39)	0.37	35 (21–58)	18 (6–30)	0.0007*
Duration of cough, days	50	Pred.	5 (2–9)	0.26	2 (0–7)	6 (4–10)	0.033†	6 (5–11)	4 (2–7)	0.10
Duration of cough, days	50	Pl.	7 (4 to13)	0.26	10 (4–13)	7 (3–12)	0.033†	7 (4–14)	8 (4–12)	0.10
Duration of dyspnea, days	50	Pred.	2 (0–4)	0.61	0 (0–2)	4 (0–5)	0.033‡	2 (0–2)	3 (0–4)	0.89
Duration of dyspnea, days	50	Pl.	2 (0–4)	0.61	2 (0–4)	2 (0–3)	0.033‡	3 (0–4)	1 (0–3)	0.89
Outpatient visit, no.§	46	Pred.	3/21 (14%)	0.61	1/5 (20%)	2/16 (13%)	0.99	2/9 (22%)	1/12 (8%)	0.49
Outpatient visit, no.§	46	Pl.	5/25 (20%)	0.61	2/8 (25%)	3/17 (18%)	0.99	4/11 (36%)	1/14 (7%)	0.49
Rehospitalized, no.§	46	Pred.	2/21 (10%)	0.79	0/5 (0%)	2/17 (12%)	0.97	2/9 (22%)	0/12 (0%)	0.97
Rehospitalized, no.§	46	Pl.	3/25 (12%)	0.79	1/8 (13%)	2/17 (12%)	0.97	2/11 (18%)	1/14 (7%)	0.97
B‐eos at discharge, ×10⁹/l	53	Pred.	0.00 (0.00–0.10)	<0.0001¶	0.00 (0.00–0.10)	0.00 (0.00–0.10)	0.52	0.050 (0.00–0.10)	0.00 (0.00–0.10)	0.16
B‐eos at discharge, ×10⁹/l	53	Pl.	0.50 (0.30–0.80)	<0.0001¶	0.40 (0.30–0.50)	0.70 (0.50–1.2)	0.52	0.70 (0.50–1.20)	0.40 (0.20–0.80)	0.16
B‐eos 2 wk after discharge, ×10⁹/l	52	Pred.	0.45 (0.30–0.70)	0.084	0.50 (0.60–0.70)	0.40 (0.20–1.30)	0.94	0.85 (0.40–1.30)	0.40 (0.30–0.60)	0.23
B‐eos 2 wk after discharge, ×10⁹/l	52	Pl.	0.30 (0.30–0.50)	0.084	0.30 (0.20–0.35)	0.40 (0.30–0.60)	0.94	0.40 (0.30–0.70)	0.30 (0.20–0.50)	0.23

Int., intervention; B‐Eos, blood eosinophils; pred., prednisolone; pl., placebo.

Values are medians (interquartile range) or number of subjects (%). Analysis using multivariate regression analysis.

*In enterovirus group, RR 3.75, 95% CI 1.99–7.08, p < 0.0001. In non‐enterovirus group, RR 0.84, 95% CI 0.50–1.39, p = 0.49.

†In rhinovirus group, RR 2.71, 95% CI 1.34–5.47, p = 0.0053. In non‐rhinovirus group, RR 1.06, 95% CI 0.67–1.68, p = 0.80.

‡In rhinovirus group, RR 4.31, 95% CI 1.12–16.64, p = 0.034. In non‐rhinovirus group, RR 0.77, 95% CI 0.33–1.78, p = 0.54.

§As a result of wheezing during 2 months after discharge.

¶RR 10.87, 95% CI 3.84–30.78.